{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:04:00Z","timestamp":1791011040730,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.neurol.2008.12.001","type":"journal-article","created":{"date-parts":[[2009,2,15]],"date-time":"2009-02-15T10:42:46Z","timestamp":1234694566000},"page":"355-365","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacologie des agents utilis\u00e9s dans l\u2019\u00e9tat de mal \u00e9pileptique"],"prefix":"10.1016","volume":"165","author":[{"given":"V.","family":"Navarro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-X.","family":"Mazoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2008.12.001_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.arcmed.2004.11.006","article-title":"Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients","volume":"36","author":"Aarons","year":"2005","journal-title":"Arch Med Res"},{"key":"10.1016\/j.neurol.2008.12.001_bib2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.63.10_suppl_4.S3","article-title":"Pharmacogenetics and enzyme induction\/inhibition properties of antiepileptic drugs","volume":"63","author":"Anderson","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2008.12.001_bib3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0022-3565(25)22081-X","article-title":"In vitro correlates of benzodiazepine cerebrospinal fluid uptake, pharmacodynamic action and peripheral distribution","volume":"227","author":"Arendt","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neurol.2008.12.001_bib4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00007691-200402000-00009","article-title":"The binding of selected therapeutic drugs to human serum alpha-1 acid glycoprotein and to human serum albumin in vitro","volume":"26","author":"Bailey","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.neurol.2008.12.001_bib5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1124\/jpet.106.102491","article-title":"Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays","volume":"320","author":"Baltes","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neurol.2008.12.001_bib6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.neuropharm.2006.07.038","article-title":"Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein","volume":"52","author":"Baltes","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neurol.2008.12.001_bib7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00003088-200544040-00005","article-title":"Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data","volume":"44","author":"Battino","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.neurol.2008.12.001_bib8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00003088-199529040-00005","article-title":"Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide","volume":"29","author":"Battino","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.neurol.2008.12.001_bib9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/(SICI)1099-081X(199907)20:5<233::AID-BDD179>3.0.CO;2-5","article-title":"Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data","volume":"20","author":"Blanco-Serrano","year":"1999","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.neurol.2008.12.001_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002826-200103000-00002","article-title":"Pharmacokinetic and pharmacodynamic analysis of sedative and amnesic effects of lorazepam in healthy volunteers","volume":"24","author":"Blin","year":"2001","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.neurol.2008.12.001_bib11","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S0140-6736(87)91097-X","article-title":"Propofol infusion and green urine","volume":"2","author":"Bodenham","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2008.12.001_bib12","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.0013-9580.2005.55204.x","article-title":"Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine","volume":"46","author":"Britzi","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2008.12.001_bib13","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00000542-198302000-00008","article-title":"The role of metabolism and protein binding in thiopental anesthesia","volume":"58","author":"Burch","year":"1983","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neurol.2008.12.001_bib14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jchromb.2004.06.012","article-title":"Studies of phenytoin binding to human serum albumin by high-performance affinity chromatography","volume":"809","author":"Chen","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.neurol.2008.12.001_bib15","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00007691-200110000-00006","article-title":"Plasma concentration of topiramate correlates with cerebrospinal fluid concentration","volume":"23","author":"Christensen","year":"2001","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.neurol.2008.12.001_bib16","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clpt.2005.02.006","article-title":"Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers","volume":"77","author":"Chung","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.neurol.2008.12.001_bib17","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1097\/00000542-199912000-00022","article-title":"Pharmacokinetics of thiopental enantiomers during and following prolonged high-dose therapy","volume":"91","author":"Cordato","year":"1999","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neurol.2008.12.001_bib18","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/j.1471-4159.1985.tb08793.x","article-title":"Blood-brain barrier transport of valproic acid","volume":"44","author":"Cornford","year":"1985","journal-title":"J Neurochem"},{"key":"10.1016\/j.neurol.2008.12.001_bib19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(00)03547-9","article-title":"Long-term propofol infusion and cardiac failure in adult head-injured patients","volume":"357","author":"Cremer","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2008.12.001_bib20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1046\/j.1365-2125.2003.01920.x","article-title":"Free and bound propofol concentrations in human cerebrospinal fluid","volume":"56","author":"Dawidowicz","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.neurol.2008.12.001_bib21","first-page":"353","article-title":"Phenytoin: blockage of resting sodium channels","volume":"27","author":"De Weer","year":"1980","journal-title":"Adv Neurol"},{"key":"10.1016\/j.neurol.2008.12.001_bib22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1113\/jphysiol.2005.092155","article-title":"Dissociated effects of diazepam and lorazepam on short-latency afferent inhibition","volume":"569","author":"Di Lazzaro","year":"2005","journal-title":"J Physiol"},{"key":"10.1016\/j.neurol.2008.12.001_bib23","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1046\/j.1365-2125.2001.00394.x","article-title":"Therapeutic drug monitoring--antiepileptic drugs","volume":"52","author":"Eadie","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.neurol.2008.12.001_bib24","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/bja\/48.10.1017","article-title":"Metabolism of lorazepam","volume":"48","author":"Elliott","year":"1976","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.neurol.2008.12.001_bib25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrn1625","article-title":"Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors","volume":"6","author":"Farrant","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.neurol.2008.12.001_bib26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00003088-200342010-00002","article-title":"Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures","volume":"42","author":"Fischer","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.neurol.2008.12.001_bib27","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1523\/JNEUROSCI.19-13-05506.1999","article-title":"Brain mechanisms of propofol-induced loss of consciousness in humans: a positron emission tomographic study","volume":"19","author":"Fiset","year":"1999","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurol.2008.12.001_bib28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0149-2918(97)80126-9","article-title":"Pharmacokinetics and pharmacodynamics of midazolam given via continuous intravenous infusion in intensive care units","volume":"19","author":"Fragen","year":"1997","journal-title":"Clin Ther"},{"key":"10.1016\/j.neurol.2008.12.001_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00002018-200629010-00001","article-title":"Valproic acid in epilepsy: pregnancy-related issues","volume":"29","author":"Genton","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.neurol.2008.12.001_bib30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/FTD.0b013e318030def0","article-title":"Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese","volume":"29","author":"Goto","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.neurol.2008.12.001_bib31","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/bja\/55.10.985","article-title":"In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution","volume":"55","author":"Greenblatt","year":"1983","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.neurol.2008.12.001_bib32","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1097\/00003246-200008000-00011","article-title":"Kinetics and dynamics of lorazepam during and after continuous intravenous infusion","volume":"28","author":"Greenblatt","year":"2000","journal-title":"Crit Care Med"},{"key":"10.1016\/j.neurol.2008.12.001_bib33","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0140-6736(99)90018-1","article-title":"Propofol-infusion syndrome in children","volume":"353","author":"Hatch","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2008.12.001_bib34","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1212\/01.WNL.0000090565.15739.8D","article-title":"Sevoflurane is epileptogenic in healthy subjects at surgical levels of anesthesia","volume":"61","author":"Jaaskelainen","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2008.12.001_bib35","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0022-3565(25)24108-8","article-title":"Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding","volume":"245","author":"Jones","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neurol.2008.12.001_bib36","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1016\/S0006-3495(01)76225-X","article-title":"Continuum solvent model studies of the interactions of an anticonvulsant drug with a lipid bilayer","volume":"80","author":"Kessel","year":"2001","journal-title":"Biophys J"},{"key":"10.1016\/j.neurol.2008.12.001_bib37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/00003088-200746040-00001","article-title":"The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications","volume":"46","author":"Klotz","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.neurol.2008.12.001_bib38","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1067\/mcp.2002.129500","article-title":"Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6\u00a0% and propofol 1\u00a0%","volume":"72","author":"Knibbe","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.neurol.2008.12.001_bib39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0163-7258(01)00122-X","article-title":"The mechanisms of action of commonly used antiepileptic drugs","volume":"90","author":"Kwan","year":"2001","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.neurol.2008.12.001_bib40","first-page":"51","article-title":"Binding of fosphenytoin, phosphate ester pro drug of phenytoin, to human serum proteins and competitive binding with carbamazepine, diazepam, phenobarbital, phenylbutazone, phenytoin, valproic acid or warfarin","volume":"88","author":"Lai","year":"1995","journal-title":"Res Commun Mol Pathol Pharmacol"},{"key":"10.1016\/j.neurol.2008.12.001_bib41","unstructured":"Lhatoo S. First London Colloquium on Status Epilepticus, 12\u201314 avril 2007."},{"key":"10.1016\/j.neurol.2008.12.001_bib42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2165\/00003088-199630010-00004","article-title":"Pharmacokinetic-pharmacodynamic relationships for benzodiazepines","volume":"30","author":"Laurijssens","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.neurol.2008.12.001_bib43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/bja\/aeg040","article-title":"Differential interaction of anaesthetics and antiepileptic drugs with neuronal Na+ channels, Ca2+ channels, and GABA(A) receptors","volume":"90","author":"Lingamaneni","year":"2003","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.neurol.2008.12.001_bib44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1124\/jpet.301.1.7","article-title":"Role of multidrug transporters in pharmacoresistance to antiepileptic drugs","volume":"301","author":"Loscher","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neurol.2008.12.001_bib45","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00023210-200721020-00005","article-title":"Various pharmacogenetic aspects of antiepileptic drug therapy: a review","volume":"21","author":"Mann","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neurol.2008.12.001_bib46","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2125.1999.00860.x","article-title":"Binding of propofol to blood components: implications for pharmacokinetics and for pharmacodynamics","volume":"47","author":"Mazoit","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.neurol.2008.12.001_bib47","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00023210-200317040-00003","article-title":"Propofol: a review of its use in intensive care sedation of adults","volume":"17","author":"McKeage","year":"2003","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neurol.2008.12.001_bib48","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00000542-200308000-00014","article-title":"Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics","volume":"99","author":"Minto","year":"2003","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neurol.2008.12.001_bib49","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.2042-7158.1983.tb04302.x","article-title":"Concentration-independent plasma protein binding of benzodiazepines","volume":"35","author":"Moschitto","year":"1983","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.neurol.2008.12.001_bib50","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1097\/00000542-200412000-00005","article-title":"Estimation of the plasma effect site equilibration rate constant (ke0) of propofol in children using the time to peak effect: comparison with adults","volume":"101","author":"Munoz","year":"2004","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neurol.2008.12.001_bib51","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1046\/j.1365-2125.2003.01829.x","article-title":"Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus","volume":"56","author":"Ogutu","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.neurol.2008.12.001_bib52","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1474-4422(03)00483-6","article-title":"Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2008.12.001_bib53","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","article-title":"Clinical pharmacokinetics of levetiracetam","volume":"43","author":"Patsalos","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.neurol.2008.12.001_bib54","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics","volume":"85","author":"Patsalos","year":"2000","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.neurol.2008.12.001_bib55","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/clpt.1982.190","article-title":"Blood-brain barrier transfer and cerebral uptake of antiepileptic drugs","volume":"32","author":"Paulson","year":"1982","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.neurol.2008.12.001_bib56","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","article-title":"Clinically relevant drug interactions with antiepileptic drugs","volume":"61","author":"Perucca","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.neurol.2008.12.001_bib57","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","article-title":"Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience","volume":"16","author":"Perucca","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neurol.2008.12.001_bib58","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0304-3940(02)00423-8","article-title":"P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats","volume":"327","author":"Potschka","year":"2002","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.neurol.2008.12.001_bib59","doi-asserted-by":"crossref","first-page":"9270","DOI":"10.1073\/pnas.93.17.9270","article-title":"Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels","volume":"93","author":"Ragsdale","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2008.12.001_bib60","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/j.1528-1167.2006.00586.x","article-title":"Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study","volume":"47","author":"Ramael","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2008.12.001_bib61","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2165\/00003088-199936060-00003","article-title":"Pharmacokinetic optimization of benzodiazepine therapy for acute seizures. Focus on delivery routes","volume":"36","author":"Rey","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.neurol.2008.12.001_bib62","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrn1430","article-title":"The neurobiology of antiepileptic drugs","volume":"5","author":"Rogawski","year":"2004","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.neurol.2008.12.001_bib63","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/00003088-199835020-00002","article-title":"Pharmacodynamics and pharmacokinetics of thiopental","volume":"35","author":"Russo","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.neurol.2008.12.001_bib64","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1097\/00000542-199805000-00006","article-title":"The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers","volume":"88","author":"Schnider","year":"1998","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neurol.2008.12.001_bib65","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/00000542-200003000-00017","article-title":"Population pharmacokinetics of propofol: a multicenter study","volume":"92","author":"Schuttler","year":"2000","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neurol.2008.12.001_bib66","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.eplepsyres.2005.01.001","article-title":"Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase","volume":"63","author":"Shank","year":"2005","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.neurol.2008.12.001_bib67","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/brain\/awf002","article-title":"Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy","volume":"125","author":"Sisodiya","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2008.12.001_bib68","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00000542-199003000-00003","article-title":"Population pharmacokinetics and pharmacodynamics of thiopental: the effect of age revisited","volume":"72","author":"Stanski","year":"1990","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neurol.2008.12.001_bib69","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00000542-198008000-00012","article-title":"Pharmacokinetics of high-dose thiopental used in cerebral resuscitation","volume":"53","author":"Stanski","year":"1980","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neurol.2008.12.001_bib70","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2125.2003.01957.x","article-title":"Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients","volume":"57","author":"Swart","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.neurol.2008.12.001_bib71","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1212\/01.WNL.0000042783.86439.27","article-title":"The use of topiramate in refractory status epilepticus","volume":"60","author":"Towne","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2008.12.001_bib72","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2174\/0929867003375335","article-title":"Propofol in anesthesia. Mechanism of action, structure-activity relationships, and drug delivery","volume":"7","author":"Trapani","year":"2000","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.neurol.2008.12.001_bib73","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000056018","article-title":"Vagal nerve stimulation for status epilepticus","volume":"34","author":"Winston","year":"2001","journal-title":"Pediatr Neurosurg"},{"key":"10.1016\/j.neurol.2008.12.001_bib74","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.2042-7158.1992.tb05514.x","article-title":"Phenobarbitone population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens","volume":"44","author":"Yukawa","year":"1992","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.neurol.2008.12.001_bib75","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003088-198815060-00002","article-title":"Clinical pharmacokinetics of valproic acid\u20141988","volume":"15","author":"Zaccara","year":"1988","journal-title":"Clin Pharmacokinet"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378708006899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378708006899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T18:32:15Z","timestamp":1738953135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378708006899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0035378708006899"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2008.12.001","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}